Pozen.

• Position: Triangle - Brief article

CHAPEL HILL -- Pozen expects to hear by mid-April whether its migraine treatment will be approved by the federal Food and Drug Administration. In August, the agency requested further study of whether Treximet, formerly known as Trexima, could cause genetic damage...